Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Current Leases (2020 - 2025)

SAB Biotherapeutics (SABS) has disclosed Current Leases for 6 consecutive years, with $797402.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Leases rose 102.68% year-over-year to $797402.0, compared with a TTM value of $797402.0 through Dec 2025, up 102.68%, and an annual FY2025 reading of $797402.0, up 102.68% over the prior year.
  • Current Leases was $797402.0 for Q4 2025 at SAB Biotherapeutics, up from $151033.0 in the prior quarter.
  • Across five years, Current Leases topped out at $1.2 million in Q3 2022 and bottomed at $127022.0 in Q2 2023.
  • Average Current Leases over 5 years is $445742.3, with a median of $384892.0 recorded in 2024.
  • The sharpest move saw Current Leases crashed 88.5% in 2023, then skyrocketed 494.15% in 2025.
  • Year by year, Current Leases stood at $161050.0 in 2021, then skyrocketed by 204.75% to $490794.0 in 2022, then soared by 36.5% to $669946.0 in 2023, then tumbled by 41.27% to $393430.0 in 2024, then surged by 102.68% to $797402.0 in 2025.
  • Business Quant data shows Current Leases for SABS at $797402.0 in Q4 2025, $151033.0 in Q3 2025, and $815064.0 in Q2 2025.